Physician

Michael B Rozboril, M.D.

According to 2025 Medicare claims, Michael Rozboril, M.D. (NPI: 1285629980) practices rheumatology in the Gainesville, FL market, with the plurality of this provider's patient population coming from Alachua, FL. This provider's primary affiliated billing organization is SIMEDHEALTH LLC (NPI: 1639680127; TIN: 823017080) and primary practice location at 32607-2824. Rozboril is affiliated with the PBACO Holding, LLC (ACO ID: A1001), participating under the MSSP model.

Rozboril's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 557 traditional Medicare patients, billed 100,060 HCPCS/CPT codes, and received $954,584 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 7,136 prescription claims across 601 beneficiaries totaling $2,090,673 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2022 DME data shows 11 claims. Open Payments data shows 7 records totaling $134. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $1,117,422 to $2,090,673. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $11,133 to $1,613.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	674	53,863	$817,173
2016	722	62,100	$980,510
2017	788	94,206	$1,251,012
2018	919	89,450	$1,266,679
2019	975	96,679	$1,312,579
2020	857	79,232	$1,063,705
2021	863	110,899	$1,278,872
2022	906	104,129	$1,108,480
2023	743	97,158	$976,795
2024	557	100,060	$954,584

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	433	6,073	$1,117,422
2016	478	4,421	$1,504,456
2017	501	4,398	$1,412,701
2018	579	4,752	$847,284
2019	636	5,268	$1,115,789
2020	648	6,222	$1,177,502
2021	670	7,330	$1,490,955
2022	631	7,201	$1,385,681
2023	575	6,800	$1,907,796
2024	601	7,136	$2,090,673

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	161	$6,963
2016	N/R	138	$5,211
2017	N/R	46	$1,697
2018	N/R	53	$2,161
2019	N/R	38	$1,427
2020	N/R	N/R	N/R
2021	N/R	36	$2,204
2022	N/R	11	$1,007
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	236	382	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	493	1,202	$59
J0897	Injection, denosumab, 1 mg	132	13,560	$20
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	251	328	$13
96372	Injection of drug or substance under skin or into muscle	149	369	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	89	2,492	$623,480
Rinvoq	Upadacitinib	69	2,250	$491,668
Xeljanz Xr	Tofacitinib Citrate	22	660	$130,656
Enbrel Mini	Etanercept	11	308	$95,562
Enbrel	Etanercept	11	308	$86,025

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$134	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael B. Rozboril, M.D.?

Tedicare shows public-source Medicare data for Michael B. Rozboril, M.D. (NPI 1285629980), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael B. Rozboril, M.D. have ACO affiliation data?

Michael B. Rozboril, M.D. is shown with ACO affiliation data for PBACO Holding, LLC (MSSP, ACO ID A1001).

What billing organization is linked to Michael B. Rozboril, M.D.?

Michael B. Rozboril, M.D. is linked to SIMEDHEALTH LLC (billing NPI 1639680127) in the available physician profile data.

Does Michael B. Rozboril, M.D. have Open Payments data?

Michael B. Rozboril, M.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.